The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Open accessAbstract
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
Bermejo-Martin, J. F., Ortiz de Lejarazu, R., Pumarola, T., Rello, J., Almansa, R., Ramírez, P., Martin-Loeches, I., Varillas, D., Gallegos, M. C., Serón, C., et al. (2009) · Critical Care · doi:10.1186/cc8208 · Cited by 373
Josset, L., Menachery, V. D., Gralinski, L. E., Agnihothram, S., Sova, P., Carter, V. S., Yount, B. L., Graham, R. L., Baric, R. S., & Katze, M. G. (2013) · mBio · doi:10.1128/mbio.00165-13 · Cited by 293
Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?
Faure, E., Poissy, J., Goffard, A., Fournier, C., Kipnis, E., Titecat, M., Bortolotti, P., Martinez, L., Dubucquoi, S., Dessein, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088716 · Cited by 248
Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS)
Tse, G. M.-K., To, K.-F., Chan, P. K.-S., Lo, A. W. I., Ng, K.-C., Wu, A., Lee, N., Wong, H.-C., Mak, S.-M., Chan, K.-F., et al. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.013276 · Cited by 238
IL-17 response mediates acute lung injury induced by the 2009 Pandemic Influenza A (H1N1) Virus
Li, C., Yang, P., Sun, Y., Li, T., Wang, C., Wang, Z., Zou, Z., Yan, Y., Wang, W., Wang, C., et al. (2012) · Cell Research · doi:10.1038/cr.2011.165 · Cited by 168
Dual Roles of IL-27 in Cancer Biology and Immunotherapy
Fabbi, M., Carbotti, G., & Ferrini, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/3958069 · Cited by 142
IL-22: There Is a Gap in Our Knowledge
Zenewicz, L. A. (2018) · ImmunoHorizons · doi:10.4049/immunohorizons.1800006 · Cited by 107
Bright, J. J., Du, C., & Sriram, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.6255 · Cited by 87
Cited by
Targeting potential drivers of COVID-19: Neutrophil extracellular traps
Barnes, B. J., Adrover, J. M., Baxter-Stoltzfus, A., Borczuk, A., Cools-Lartigue, J., Crawford, J. M., Daßler-Plenker, J., Guerci, P., Huynh, C., Knight, J. S., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200652 · Cited by 1,486
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease
Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C., & Melguizo-Rodríguez, L. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.001 · Cited by 1,121
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,114
Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G., Voors, A. A., Osterhaus, A. D., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5471 · Cited by 1,081
Aging in COVID-19: Vulnerability, immunity and intervention
Chen, Y., Klein, S. L., Garibaldi, B. T., Li, H., Wu, C., Osevala, N. M., Li, T., Margolick, J. B., Pawelec, G., & Leng, S. X. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101205 · Cited by 1,007
COVID-19: immunopathogenesis and Immunotherapeutics
Yang, L., Liu, S., Liu, J., Zhang, Z., Wan, X., Huang, B., Chen, Y., & Zhang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00243-2 · Cited by 912
COVID-19 and the human innate immune system
Schultze, J. L., & Aschenbrenner, A. C. (2021) · Cell · doi:10.1016/j.cell.2021.02.029 · Cited by 714
“…(Xiong et al., 2020) but also in the circulation (IL-1, IFNg, IL-17, TNF, IP-10, MCP-1, G-CSF, GM-CSF, IL-1RA, CCL2, CCL3, CCL5, CCL8, CXCL2, CXCL8, CXCL9, and CXCL16) (Blanco-Melo et al., 2020; Hadjadj et al., 2020; Huang et al., 2020; Wang et al., 2020a; Wu and Yang, 2020; Yang et al., 2020b).”
BackgroundInfluentialWang, J., Jiang, M., Chen, X., & Montaner, L. J. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3covr0520-272r · Cited by 741
COVID-19 infection: an overview on cytokine storm and related interventions
Montazersaheb, S., Hosseiniyan Khatibi, S. M., Hejazi, M. S., Tarhriz, V., Farjami, A., Ghasemian Sorbeni, F., Farahzadi, R., & Ghasemnejad, T. (2022) · Virology Journal · doi:10.1186/s12985-022-01814-1 · Cited by 610
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
TUFAN, A., AVANOĞLU GÜLER, A., & MATUCCI-CERINIC, M. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-168 · Cited by 495
Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection
Netea, M. G., Giamarellos-Bourboulis, E. J., Domínguez-Andrés, J., Curtis, N., van Crevel, R., van de Veerdonk, F. L., & Bonten, M. (2020) · Cell · doi:10.1016/j.cell.2020.04.042 · Cited by 468
Kell, D. B., Heyden, E. L., & Pretorius, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01221 · Cited by 460
COVID-19 cytokine storm: the anger of inflammation
Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S., & Nabipour, I. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155151 · Cited by 461
“Therefore, targeting IL-17 and T helper 17 responses in the cytokine storm of COVID19 have been suggested [8,118].”
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19
Stefan, N., Birkenfeld, A. L., & Schulze, M. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00462-1 · Cited by 452
Psychiatric and neuropsychiatric sequelae of COVID-19 – A systematic review
Schou, T. M., Joca, S., Wegener, G., & Bay-Richter, C. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.07.018 · Cited by 410
Neurological Involvement in COVID-19 and Potential Mechanisms: A Review
Aghagoli, G., Gallo Marin, B., Katchur, N. J., Chaves-Sell, F., Asaad, W. F., & Murphy, S. A. (2021) · Neurocritical Care · doi:10.1007/s12028-020-01049-4 · Cited by 357
Thyrotoxicosis in patients with COVID-19: the THYRCOV study
Lania, A., Sandri, M. T., Cellini, M., Mirani, M., Lavezzi, E., & Mazziotti, G. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0335 · Cited by 355
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
Schett, G., Sticherling, M., & Neurath, M. F. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0312-7 · Cited by 349
The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?
Darif, D., Hammi, I., Kihel, A., El Idrissi Saik, I., Guessous, F., & Akarid, K. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.104799 · Cited by 326
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19
Rodríguez, Y., Novelli, L., Rojas, M., De Santis, M., Acosta-Ampudia, Y., Monsalve, D. M., Ramírez-Santana, C., Costanzo, A., Ridgway, W. M., Ansari, A. A., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102506 · Cited by 312
COVID-19 and immunomodulation in IBD
Neurath, M. F. (2020) · Gut · doi:10.1136/gutjnl-2020-321269 · Cited by 302
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
Luo, W., Li, Y.-X., Jiang, L.-J., Chen, Q., Wang, T., & Ye, D.-W. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.007 · Cited by 296
COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation
Kempuraj, D., Selvakumar, G. P., Ahmed, M. E., Raikwar, S. P., Thangavel, R., Khan, A., Zaheer, S. A., Iyer, S. S., Burton, C., James, D., et al. (2020) · The Neuroscientist · doi:10.1177/1073858420941476 · Cited by 289
Najjar, S., Najjar, A., Chong, D. J., Pramanik, B. K., Kirsch, C., Kuzniecky, R. I., Pacia, S. V., & Azhar, S. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01896-0 · Cited by 282
COVID-19: Characteristics and Therapeutics
Chilamakuri, R., & Agarwal, S. (2021) · Cells · doi:10.3390/cells10020206 · Cited by 282
COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies
Rawat, K., Kumari, P., & Saha, L. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173751 · Cited by 276
The immune system and COVID-19: Friend or foe?
Yazdanpanah, F., Hamblin, M. R., & Rezaei, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117900 · Cited by 270
Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19
Tomar, B., Anders, H.-J., Desai, J., & Mulay, S. R. (2020) · Cells · doi:10.3390/cells9061383 · Cited by 263
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
Copaescu, A., Smibert, O., Gibson, A., Phillips, E. J., & Trubiano, J. A. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.001 · Cited by 262
Wang, Y., Zheng, J., Islam, M. S., Yang, Y., Hu, Y., & Chen, X. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59534 · Cited by 71
Mansour, H. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102195 · Cited by 3
Metadata
- Authors
- Wu, D., & Yang, X. O.
- Venue
- Journal of Microbiology, Immunology and Infection
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 53
- Issue
- 3
- Pages
- 368-370
- ISSN
- 1684-1182 (ISSN-L)
- OpenAlex
- W3012515447
- Cited by
- 785
- References
- 10
- FWCI
- 21.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.